Malvinder Mohan Singh is the Chairman, CEO and of Ranbaxy Laboratories Ltd. (Ranbaxy).

His company targets a sales target of US $5 Bn, by 2012. He has played a pivotal role in the companys management and global operations. He finished his graduation in Economics from St. Stephens college, New Delhi, India. He took a Masters Degree course in Business Administration (MBA) from the Fuqua School of Business, Duke University, USA. He had earlier worked as President, Pharmaceuticals and Executive Director at Ranbaxy, handling the global operations covering Pharmaceuticals, API and Manufacturing spread across 49 countries. He also led the companys India operations as Regional Director. He has expertise in diversified fields of General Management, Sales & Marketing, Finance and Business Development. He is a member of the National Council for the Confederation of Indian Industries (CII). He is also the Co- Chairman of the National committee on Intellectual Property Rights (IPR), CII. Recently, he was nominated to the prestigious forum of insightful, innovative and energetic Young Global Leaders, World Economic Forum.

Malvinder Mohan Singh is the son of Dr. Parvinder Singh, and is the former Chairman and CEO of Ranbaxy Laboratories.[1] He is the grandson of Bhai Mohan Singh, the founder of Ranbaxy. He and his brother Shivinder Singh are among the top twenty richest Indians in the world. They have a nephew Rakshay Singh who is currently taking MBA so that he can be a helping hand.[2] Singh attended The Doon School and St. Stephens College. He also received his MBA from Duke University's Fuqua School of Business.[3] He was awarded Indian Entrepreur of the Year 2011 by Horasis [4] [5] He is the chairman of following companies: Fortis Hospitals Religare Financial Services Religare Technova Religare Voyage Religare Vistar Films

Malvinder and Shivinder Singh Biography

Malvinder and Shivinder Singh are the brothers and Forbes Billionaire Business Tycoons of India. Their Net Worth is US $ 3.2 Billion according to Forbes 2010. They are one of the most richest persons of India.

Both the Brothers inherited the familys pharmaceutical firm, Ranbaxy Laboratories Limited which they grew to make it US $ 1.2 Billion Sales.

Malvinder was a president of Ranbaxy Labs up to 2008 which he later on sold to Daichii in 2008 for whooping US $ 2 Billion (Rs.10,000 Crores) and exit from the Business.

The Younger Brother Shivinder runs the Fortis, The Familys Hospital Chain.

Malvinder Singh is the son of Dr.Parvinder Singh, the former chairman of Ranbaxy Laboratories

Malvinder and Shivinder Singh Education -

Malvinder & Shivinder Singh attended St. Stephens College. He also received his MBA from Duke University's Fuqua School of Business.

Ranbaxy Labs: Corporate Profile

Ranbaxy Laboratories Limited (BSE: 500359) is India's largest pharmaceutical company. Incorporated in 1961, Ranbaxy exports its products to 125 countries with ground operations in 46 and manufacturing facilities in seven countries. The company went public in 1973, and Japanese company Daiichi Sankyo gained majority control in 2008.

On June 11, 2008, Daiichi-Sankyo acquired a 34.8% stake in Ranbaxy, for a value $2.4 billion. In November 2008, Daiichi-Sankyo completed the takeover of the company from the founding Singh family in a deal worth $4.6 billion by acquiring a 63.92% stake in Ranbaxy.

Malvinder Singh is a member of the National Council for the Confederation of Indian Industries (CII). He is also the Co- Chairman of the National committee on Intellectual Property Rights (IPR), CII. Recently, he was nominated to the prestigious

forum of insightful, innovative and energetic Young Global Leaders, World Economic Forum.
Dr Tempest is to continue with RLL as chief mentor and executive vice chairman of the Board. Dr Tempest has another year's contract with the company. Announcing the decision at a press conference here today, Ramesh L. Adige, vice president, corporate affairs, global corporate communications and executive director, RLL said that the new CMD assumes complete operational responsibility for the company and will focus on spearheading Ranbaxy's growth to its target of achieving USD 5 billion of global sales by 2012. Speaking on the occasion, Malvinder Singh expressed strong optimism about the company's future and observed that it is poised for significant growth across global markets. Commenting on the poor performance of the company during the Year 2005, Malvinder Singh hoped to reverse the trend through reduced litigation costs and lesser R&D expenditure. Dr Brian Tempest considered the top management shakeup as part of effective succession planning at the top level. Prior to his current position as president, Malvinder Singh led the company's India operations as regional director, soon after his successful tenure as director, global licensing and business development. Singh joined Ranbaxy in 1998 and has worked through various functions of general management, sales and marketing, finance and business development.